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Metronidazole (Mz)-resistant Giardia and Trichomonas were inhibited by 1 of 30 new 5-nitroimidazole drugs.
Another five drugs were effective against some but not all of the Mz-resistant parasites. This study provides the
incentive for the continued design of 5-nitroimidazole drugs to bypass cross-resistance among established
5-nitromidazole antiparasitic drugs.
Metronidazole (Mz) and a related 5-nitroimidazole, tinida-
zole, are the only drugs recommended for the treatment of
trichomoniasis and are the most-prescribed drugs for the treat-
ment of giardiasis. However, clinical resistance to these drugs
has been well documented; and in the event of overt clinical
resistance to Mz in trichomonads, there is no alternative for
treatment, when one keeps in mind the documented cross-
resistance between the currently used 5-nitroimidazole drugs
and their worldwide availability (7, 8, 18, 23). Some success has
been obtained with quinacrine and albendazole in combination
with Mz in cases of giardiasis treatment failures (23). On the
positive side, a great deal of flexibility is offered by the side
chains attached to the imidazole ring structure that bear the all
important nitro group (17).
The mechanisms of Mz resistance in Giardia and Trichomo-
nas have been well studied in laboratory-induced resistance
(18). It occurs by down-regulation of pathways, especially the
enzyme pyruvate:ferredoxin oxidoreductase (PFOR) and
ferredoxin (Fd) pathway, that activate Mz to its toxic radical
state. The PFOR-Fd couple has an electron potential suffi-
ciently low to activate Mz, while no such electron couple is
present in the mammalian host (9). In the laboratory we see a
threefold down-regulation of PFOR activity in Mz-resistant
(Mzr) Giardia duodenalis (14), and in highly Mzr Trichomonas
vaginalis the activity of the hydrogenosome organelle is down-
regulated such that there is no detectable PFOR or Fd expres-
sion (4, 11, 18). Thus, Mz is not activated to its toxic radical
state in these cells. On the other hand, it is well documented
that clinically Mzr T. vaginalis strains do not have down-regu-
lated hydrogenosomes, and the mechanism of Mz resistance in
these cells is not understood (8).
Previously, we showed that some 5-nitroimidazole deriva-
tives were significantly more effective antiprotozoal agents
(based on in vitro molar drug concentrations) than Mz against
Mz-susceptible (Mzs) parasites but were not as effective against
Mzr parasites (17). Given the impetus for the development of
5-nitroimidazole drugs that vary markedly in their efficacies
(both positively and negatively), we tested 30 new 5-nitroim-
idazoles in our anaerobic drug susceptibility screening assay
(16) for their efficacies against T. vaginalis and G. duodenalis,
with the focus on laboratory-derived Mzr (Mzrl) lines and clin-
ical isolates derived from patients with treatment failures.
Parasites were cultured axenically in anaerobic TYI-S-33
(6), which was modified as described previously (16). Mzs G.
duodenalis isolates WB-1B, BRIS/87/HEPU/713 (713), and
BRIS/83/HEPU/106 (106) were tested along with their respec-
tive Mzrl lines WB-M3, 713-M3, and 106-2ID10 (13, 16). Mz
s T.
vaginalis isolate BRIS/92/HEPU/F1623 (F1623) and the highly
Mzrl line derived from it, F1623-M1 (16), were used through-
out. BRIS/92/HEPU/7268 (B7268) (16) and DUR/03/
FMUN/36 (DUR36) were the T. vaginalis Mzr clinical (Mzrc)
isolates used. Breakpoints for susceptibility versus resistance to
Mz were previously described as an MIC of 3.2 M (with a
maximum of 6.3 M and minimum of 1.6 M) for Mzs T.
vaginalis and 6.3 M (with a minimum of 3.2 M and maxi-
mum of 12.5 M in a few cases) for Mzs G. duodenalis (16).
The minimum MIC among all assays for Mzr parasites was 25
M (16). For the purposes of screening new 5-nitroimidazoles,
we have directly compared their MICs with those for Mz.
All new 5-nitroimidazole compounds (Fig. 1) were identified
by spectral data, purified by chromatography on silica gel col-
umns, and recrystallized from appropriate solvents. Their pu-
rities were checked with appropriate controls by thin-layer
chromatography and elemental analysis (C, H, N). The purity
was always over 99.6%. The synthesis of compounds 1 to 9, 10
to 16, 17 to 19, 20 to 23, and 24 to 28 were as described in
references 2, 1, 20, 21, and 22, respectively. The reaction of
compound 28 with 2-nitropropane or nitrocyclohexane anion
led to the C-alkylation products 29 and 30, respectively, by the
SRN1 mechanism.
Of the 30 compounds tested, compounds 11, 12, 13, 24, 26,
and 30 demonstrated MICs against all three Mzs G. duodenalis
isolates of 100 M (Mz MIC  10 M) (data not shown).
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FIG. 1. Structures of the 5-nitroimidazole drugs used in this study compared with that of Mz. MW, molecular weight.
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Compounds 6, 10, 15, 16, 19, 20, 21, 22, 23, 28, and 29 had
higher MICs than Mz against one or more of the Mzs isolates
tested (data not shown). As a result, these drugs were not
considered further, except where stated below.
Compounds 1, 2, 3, 4, 5, 7, 8, 9, 14, 17, 18, 25, and 27
demonstrated MICs equal to or less than that of Mz (10 M)
for all Mzs Giardia and Trichomonas isolates tested and were
subsequently assessed against all the Mzrl and Mzrc parasites
described above. Of these compounds, compounds 1, 2, 4, 5, 9,
25, and 27 were similarly as ineffective as Mz against Mzrl
Giardia WB-M3 and 713-M3 (MICs  50 M for one or both
lines) (data not shown). Compounds 3, 7, 8, 14, 17, and 18 were
10-fold more inhibitory than Mz against all Mzrl Giardia
(Table 1). In addition, compound 14 had the same MICs of 1
M (Table 1 and data not shown) against both Mzs and Mzr
Giardia parasites. Of these six most effective antigiardial drugs,
compound 14 was 16- to 100-fold more inhibitory than Mz
against all Mzr parasites (Table 1); compounds 17 and 18 were
effective against Mzrc T. vaginalis isolates (fivefold or greater
more inhibitory than Mz) but not against Mzrl T. vaginalis
(MICs  50 and 25 M, respectively) (Table 1); and com-
pounds 3, 7, and 8 were effective only against T. vaginalis Mzrc
isolate DUR36 (10- to 16-fold more inhibitory than Mz) (Table
1). The significance of the data presented in Table 1 is the low
in vitro MICs for six 5-nitroimidazole compounds against some
or all of the Mzr parasites tested. No other 5-nitroimidazole
compounds tested so far were inhibitory to the Mzr parasites
used in this study.
The most effective drug overall, compound 14, differs in
structure from compound 16 (Fig. 1) by the remote substitu-
ents of the side chain attached at the 2 position on the nitro-
imidazole ring, notably, a nitro group in compound 14 but not
in compound 16, which showed no inhibition of two Mzs G.
duodenalis isolates (MICs  100 M). Other compounds with
remote nitro groups (compounds 20, 21, 22, 23, 29, and 30; Fig.
1) did not inhibit Mzr parasites (MICs  100 M). We also
tested a number of quinoxaline and 3,4-diphenylfuran deriva-
tives with and without nitro groups (unpublished synthesis
data) and p-nitrobenzyl derivatives (3), none of which were
effective antiprotozoal agents (data not shown).
Of the highly effective antitrichomonal 5-nitroimidazoles,
compound 17 was selected for extended studies, due to its
inhibition of Mzrc T. vaginalis (Table 1) and its ease of
preparation. We measured the anaerobic MICs (16) of com-
pound 17 and Mz against 31 T. vaginalis clinical isolates
collected in South Africa. All Mzs isolates were susceptible
to compound 17, with at least fourfold lower MICs than that
of Mz (data not shown). Four isolates demonstrated some
level of Mz resistance (MICs for Mz of 12.5, 12.5, 50, and
100 M, respectively) but had MICs with compound 17 of
1.6, 3.1, 6.3, and 6.3 M, respectively. The most highly Mzr
isolate was DUR36 (Table 1). Compounds 14, 17, and 18
therefore provide precedence for the design of new 5-nitro-
imidazole antitrichomonal drugs. It has been claimed that
the eradication of trichomoniasis may well be the single
most cost-effective step in human immunodeficiency virus
infection incidence reduction (5, 10, 12), and for this reason
the development of drugs for the treatment of cases of Mzrc
T. vaginalis has been a focus of our work (8, 16).
Previously, we reported that among a 5-nitroimidazole series
of compounds, the most antimicrobial and antiparasitic com-
pounds showed a greater resonance conjugation in the molec-
ular structure (17, 19). For this study, we have synthesized
under mild conditions and in good yields highly conjugated
5-nitroimidazole derivatives using electron transfer reactions
(SRN1, LD-SRN1, bis-SRN1, and ERC1 [1, 2, 20, 21, 22]). By
increasing the conjugated system, we have developed some
highly active compounds, especially the C-alkylation products
obtained by LD-SRN1, compounds 8 and 14. The present study
again demonstrates the importance of the 5-nitroimidazole
side chain in antiparasitic activity (e.g., compounds 3 and 7 are
E and Z isomers, and the differences between the antiproto-
zoal activities of compounds 14 and 16 and between com-
pounds 18 and 19). These dramatic differences may relate to
solubility and membrane permeability. The positive influence
of bromine (compound 17), a sulfonyl group (compounds 3
and 7), or a dioxole nucleus (compound 18) were noted, but
deprotection of the remote dioxole ring in compound 18 re-
sulted in the formation of the diphenol compound 19, which
was detrimental to protozoocidal activity.
These data suggest that the 5-nitro group is highly active in
compound 14, but it does not explain why this drug is so active
against Mzrl T. vaginalis, which supposedly does not have the
ability to reduce Mz (4). We have previously identified alter-
native 2 oxoacid oxidoreductase (OR) activity in Mzrl T. vagi-
nalis (4), and it is possible that these alternative ORs are
responsible for the activation of compound 14 to its toxic
radical state.
There are examples in the literature of patients who have
failed to respond to all antigiardial or antitrichomonal treat-
ments (7, 23). Here we have shown that at least three different
5-nitroimidazole compounds, including one that is readily syn-
thesized, inhibited highly Mzrl G. duodenalis and Mzrc T. vagi-
nalis isolates. The clinical application of such drugs may well
overcome the documented cross-resistance among the 5-nitro-
imidazole drugs, and the lead compounds described here pro-
vide the basis from which new 5-nitroimidazole drugs clinically
active against Mzr Trichomonas and Giardia can be derived.
TABLE 1. Comparison of MICs of the six most effective new 5-
nitroimidazole drugs against Mzr G. duodenalis and T. vaginalis lines
and isolates
Druga
MIC (M)
Mzrl Giardia Trichomonas
WB-M3 713-M3 106-2ID10
Mzrl F1623-
M1
Mzrc
B7268 DUR36c
Mz 50 100 50 50 50 100
14 1 1 1 1 3.1 1.6
18 1 0.5 1 25 6.3 6.3
17 5 10 5 50 10 6.3
8 3.1 5 NDb 50 50 6.3
7 3.1 5 ND 50 50 6.3
3 3.1 1 ND 50 50 10
a drugs are listed in the order of their efficacies.
b ND, not done.
c Isolate collected in Durban, South Africa and established in culture at the
Faculty of Medicine, University of Natal.
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